Clinical

The analysis could help investigators better understand why a subset of patients with advanced melanoma develops resistance or does not respond to targeted therapy.

When excluding the price tag of treatment, costs were significantly lower among the patients identified by early screening than among the patients identified by symptoms

Dr Dietrich discusses patients acquiring and providers managing resistance to KRAS inhibition.

Alexander Spira, MD, PhD, FACP, and Joshua Sabari, MD, detail possible therapeutic options for KRAS-mutated NSCLC, focusing on adagrasib and treating brain metastases.

Dr Kristen Ciombor explores clinical impacts during the treatment of patients with metastatic or nonmetastatic colorectal cancer.

Ryan Haumschild, PharmD, MS, MBA, reviews risk factors for colorectal cancer, including social determinants and at-risk demographics.

Our experts conclude by interpreting ways to better educate both payers and providers on PDTs.

Diana Brixner, RPh, PhD, comments on how incorporating value-based pilot programs would impact her decision-making with PDT coverage as a payer.

Participants in a digital acute musculoskeletal (MSK) program experienced better pain and function outcomes vs nonparticipants, demonstrating benefits for acute and subacute MSK conditions.

The study is one of the first to analyze the negative impact of particulate matter and the use of biomass fuel on lung function for young adults in lower–middle income countries.

Researchers of this new study found that treatment with venetoclax may be able to restore activation and proliferation of these cells, suggesting their plasticity can be leveraged for autologous T-cell–based treatments.

Few data exist on how right ventricular fractional area change (RVFAC) may contribute to outcomes among patients hospitalized for heart failure, so that potential relationship was investigated in this new study from Japan.

Researchers have found that patients who have idiopathic pulmonary arterial hypertension (IPAH) with a phenotype characterized by a smoking history and low diffusion capacity for carbon monoxide had little in common with patients with classical IPAH.

The oncology space has seen successful adoption of biosimilars thanks to processes and formulary decisions driving conversion rates.

Successful comprehensive genomic profiling of tissue samples among patients with lung cancer was more likely to occur when samples were extracted via resections vs fluid cytology, biopsy, or fine-needle aspirations.

A recent study found that older age, male sex, residence in a long-term care home, and chronic kidney disease were shared predictors of increased mortality for patients hospitalized with influenza, respiratory syncytial virus, or SARS-CoV-2.

Although the autoimmune response that reduces β cell numbers has often been the focus of research in type 1 diabetes (T1D), findings from a new study suggest proinflammatory signaling in islet β cells may play a significant role in disease progression.

Researchers have found that resistance to the BCL2 inhibitor was driven by methylation and epigenetic silencing of PUMA.

Dr Sabari highlights typical outcomes for patients with NSCLC vs KRAS G12C-mutated NSCLC, as well as challenges associated with targeted treatments.

Martin Dietrich, MD, PhD, explains what KRAS G12C mutations in NSCLC are and how common they are within the NSCLC landscape.

Knowing that insulin requirements vary widely among persons who have type 1 diabetes, 3-month effectiveness of the Omnipod 5 Automated Insulin Delivery System was evaluated across 6 daily insulin doses.

Drs Podesta and Brixner discuss possible ways to improve access to PDTs for every party involved—patient, payer, and provider.

Two medical experts relay their ideas on how to better improve the payer-provider relationship surrounding PDT use.

Daniel Culver, DO, details how COVID-19 has impacted the treatment of ILD.

Kristin Highland, MD, and Ryan Haumschild, PharmD, MS, MBA, compare management tools to self-regulation for the best ILD treatment outcome, as well as patient access to nintedanib, pirfenidone, and tocilizumab through special pharmacies.